nodes	percent_of_prediction	percent_of_DWPC	metapath
Metyrapone—ABCC3—Vincristine—kidney cancer	0.211	0.318	CbGbCtD
Metyrapone—ABCC3—Doxorubicin—kidney cancer	0.132	0.199	CbGbCtD
Metyrapone—CYP3A4—Everolimus—kidney cancer	0.0935	0.141	CbGbCtD
Metyrapone—CYP3A4—Temsirolimus—kidney cancer	0.0632	0.0955	CbGbCtD
Metyrapone—CYP3A4—Pazopanib—kidney cancer	0.0332	0.0502	CbGbCtD
Metyrapone—CYP3A4—Erlotinib—kidney cancer	0.0237	0.0358	CbGbCtD
Metyrapone—CYP3A4—Paclitaxel—kidney cancer	0.0217	0.0328	CbGbCtD
Metyrapone—CYP3A4—Sorafenib—kidney cancer	0.0193	0.0291	CbGbCtD
Metyrapone—CYP3A4—Vinblastine—kidney cancer	0.019	0.0287	CbGbCtD
Metyrapone—CYP3A4—Vincristine—kidney cancer	0.0187	0.0282	CbGbCtD
Metyrapone—CYP3A4—Sunitinib—kidney cancer	0.0156	0.0236	CbGbCtD
Metyrapone—Adrenal insufficiency—Sunitinib—kidney cancer	0.012	0.0541	CcSEcCtD
Metyrapone—CYP3A4—Doxorubicin—kidney cancer	0.0117	0.0177	CbGbCtD
Metyrapone—White blood cell count decreased—Temsirolimus—kidney cancer	0.00816	0.0366	CcSEcCtD
Metyrapone—White blood cell count decreased—Pazopanib—kidney cancer	0.00769	0.0345	CcSEcCtD
Metyrapone—White blood cell count decreased—Everolimus—kidney cancer	0.00607	0.0273	CcSEcCtD
Metyrapone—Hirsutism—Everolimus—kidney cancer	0.0052	0.0233	CcSEcCtD
Metyrapone—White blood cell count decreased—Sunitinib—kidney cancer	0.00507	0.0228	CcSEcCtD
Metyrapone—Hirsutism—Erlotinib—kidney cancer	0.00501	0.0225	CcSEcCtD
Metyrapone—Endocrine disorder—Pazopanib—kidney cancer	0.00461	0.0207	CcSEcCtD
Metyrapone—Endocrine disorder—Everolimus—kidney cancer	0.00364	0.0164	CcSEcCtD
Metyrapone—Endocrine disorder—Sorafenib—kidney cancer	0.00316	0.0142	CcSEcCtD
Metyrapone—Bone marrow depression—Vincristine—kidney cancer	0.00316	0.0142	CcSEcCtD
Metyrapone—Endocrine disorder—Sunitinib—kidney cancer	0.00304	0.0137	CcSEcCtD
Metyrapone—Dermatitis atopic—Gemcitabine—kidney cancer	0.00273	0.0123	CcSEcCtD
Metyrapone—Hirsutism—Capecitabine—kidney cancer	0.00239	0.0107	CcSEcCtD
Metyrapone—Dermatitis atopic—Paclitaxel—kidney cancer	0.00229	0.0103	CcSEcCtD
Metyrapone—Bone marrow depression—Capecitabine—kidney cancer	0.00206	0.00925	CcSEcCtD
Metyrapone—Angiopathy—Temsirolimus—kidney cancer	0.00185	0.00831	CcSEcCtD
Metyrapone—Pancytopenia—Vinblastine—kidney cancer	0.00181	0.00811	CcSEcCtD
Metyrapone—Pancytopenia—Everolimus—kidney cancer	0.0018	0.00808	CcSEcCtD
Metyrapone—Angiopathy—Pazopanib—kidney cancer	0.00174	0.00783	CcSEcCtD
Metyrapone—Alopecia—Pazopanib—kidney cancer	0.0017	0.00762	CcSEcCtD
Metyrapone—Abdominal discomfort—Sorafenib—kidney cancer	0.00158	0.00708	CcSEcCtD
Metyrapone—Hypertension—Temsirolimus—kidney cancer	0.00153	0.00688	CcSEcCtD
Metyrapone—Abdominal discomfort—Sunitinib—kidney cancer	0.00152	0.00681	CcSEcCtD
Metyrapone—Pancytopenia—Sunitinib—kidney cancer	0.0015	0.00675	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.0015	0.00674	CcSEcCtD
Metyrapone—Hypertension—Pazopanib—kidney cancer	0.00144	0.00648	CcSEcCtD
Metyrapone—Pancytopenia—Dactinomycin—kidney cancer	0.00142	0.00639	CcSEcCtD
Metyrapone—Nervous system disorder—Temsirolimus—kidney cancer	0.00142	0.00638	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00141	0.00635	CcSEcCtD
Metyrapone—Skin disorder—Temsirolimus—kidney cancer	0.00141	0.00632	CcSEcCtD
Metyrapone—Angiopathy—Everolimus—kidney cancer	0.00138	0.00618	CcSEcCtD
Metyrapone—Alopecia—Vinblastine—kidney cancer	0.00135	0.00604	CcSEcCtD
Metyrapone—Alopecia—Everolimus—kidney cancer	0.00134	0.00602	CcSEcCtD
Metyrapone—Nervous system disorder—Pazopanib—kidney cancer	0.00134	0.00601	CcSEcCtD
Metyrapone—Bone marrow depression—Doxorubicin—kidney cancer	0.00133	0.00596	CcSEcCtD
Metyrapone—Skin disorder—Pazopanib—kidney cancer	0.00133	0.00595	CcSEcCtD
Metyrapone—Alopecia—Erlotinib—kidney cancer	0.00129	0.00581	CcSEcCtD
Metyrapone—Pancytopenia—Vincristine—kidney cancer	0.00127	0.00571	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Temsirolimus—kidney cancer	0.00125	0.00562	CcSEcCtD
Metyrapone—Pain—Temsirolimus—kidney cancer	0.00124	0.00556	CcSEcCtD
Metyrapone—Dermatitis atopic—Doxorubicin—kidney cancer	0.00121	0.00544	CcSEcCtD
Metyrapone—Pancytopenia—Gemcitabine—kidney cancer	0.00121	0.00542	CcSEcCtD
Metyrapone—Angiopathy—Sorafenib—kidney cancer	0.00119	0.00536	CcSEcCtD
Metyrapone—Gastrointestinal pain—Temsirolimus—kidney cancer	0.00118	0.00532	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00118	0.00529	CcSEcCtD
Metyrapone—Pain—Pazopanib—kidney cancer	0.00117	0.00524	CcSEcCtD
Metyrapone—Alopecia—Sorafenib—kidney cancer	0.00116	0.00522	CcSEcCtD
Metyrapone—Angiopathy—Sunitinib—kidney cancer	0.00115	0.00516	CcSEcCtD
Metyrapone—Abdominal pain—Temsirolimus—kidney cancer	0.00114	0.00514	CcSEcCtD
Metyrapone—Hypertension—Vinblastine—kidney cancer	0.00114	0.00514	CcSEcCtD
Metyrapone—Hypertension—Everolimus—kidney cancer	0.00114	0.00512	CcSEcCtD
Metyrapone—Alopecia—Sunitinib—kidney cancer	0.00112	0.00503	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00112	0.00501	CcSEcCtD
Metyrapone—Gastrointestinal pain—Pazopanib—kidney cancer	0.00112	0.00501	CcSEcCtD
Metyrapone—Abdominal pain—Pazopanib—kidney cancer	0.00108	0.00484	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.00108	0.00484	CcSEcCtD
Metyrapone—Alopecia—Dactinomycin—kidney cancer	0.00106	0.00476	CcSEcCtD
Metyrapone—Nervous system disorder—Everolimus—kidney cancer	0.00106	0.00475	CcSEcCtD
Metyrapone—Skin disorder—Everolimus—kidney cancer	0.00105	0.0047	CcSEcCtD
Metyrapone—Nervous system disorder—Erlotinib—kidney cancer	0.00102	0.00458	CcSEcCtD
Metyrapone—Skin disorder—Erlotinib—kidney cancer	0.00101	0.00453	CcSEcCtD
Metyrapone—Pancytopenia—Paclitaxel—kidney cancer	0.00101	0.00453	CcSEcCtD
Metyrapone—Hypotension—Everolimus—kidney cancer	0.00101	0.00452	CcSEcCtD
Metyrapone—Hypertension—Sorafenib—kidney cancer	0.000989	0.00444	CcSEcCtD
Metyrapone—Angiopathy—Vincristine—kidney cancer	0.000972	0.00437	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.000969	0.00435	CcSEcCtD
Metyrapone—Dizziness—Temsirolimus—kidney cancer	0.000958	0.0043	CcSEcCtD
Metyrapone—Hypertension—Sunitinib—kidney cancer	0.000952	0.00428	CcSEcCtD
Metyrapone—Alopecia—Vincristine—kidney cancer	0.000947	0.00425	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.000932	0.00419	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Everolimus—kidney cancer	0.00093	0.00418	CcSEcCtD
Metyrapone—Pain—Vinblastine—kidney cancer	0.000925	0.00415	CcSEcCtD
Metyrapone—Angiopathy—Gemcitabine—kidney cancer	0.000922	0.00414	CcSEcCtD
Metyrapone—Pain—Everolimus—kidney cancer	0.000921	0.00414	CcSEcCtD
Metyrapone—Vomiting—Temsirolimus—kidney cancer	0.000921	0.00414	CcSEcCtD
Metyrapone—Nervous system disorder—Sorafenib—kidney cancer	0.000917	0.00412	CcSEcCtD
Metyrapone—Skin disorder—Sorafenib—kidney cancer	0.000908	0.00408	CcSEcCtD
Metyrapone—Headache—Temsirolimus—kidney cancer	0.000907	0.00408	CcSEcCtD
Metyrapone—Dizziness—Pazopanib—kidney cancer	0.000902	0.00405	CcSEcCtD
Metyrapone—Alopecia—Gemcitabine—kidney cancer	0.000898	0.00403	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000897	0.00403	CcSEcCtD
Metyrapone—Pain—Erlotinib—kidney cancer	0.000889	0.00399	CcSEcCtD
Metyrapone—Gastrointestinal pain—Vinblastine—kidney cancer	0.000884	0.00397	CcSEcCtD
Metyrapone—Nervous system disorder—Sunitinib—kidney cancer	0.000882	0.00396	CcSEcCtD
Metyrapone—Gastrointestinal pain—Everolimus—kidney cancer	0.000881	0.00396	CcSEcCtD
Metyrapone—Skin disorder—Sunitinib—kidney cancer	0.000874	0.00393	CcSEcCtD
Metyrapone—Vomiting—Pazopanib—kidney cancer	0.000868	0.0039	CcSEcCtD
Metyrapone—Nausea—Temsirolimus—kidney cancer	0.00086	0.00386	CcSEcCtD
Metyrapone—Abdominal pain—Vinblastine—kidney cancer	0.000855	0.00384	CcSEcCtD
Metyrapone—Headache—Pazopanib—kidney cancer	0.000855	0.00384	CcSEcCtD
Metyrapone—Abdominal pain—Everolimus—kidney cancer	0.000852	0.00383	CcSEcCtD
Metyrapone—Gastrointestinal pain—Erlotinib—kidney cancer	0.00085	0.00382	CcSEcCtD
Metyrapone—Abdominal discomfort—Capecitabine—kidney cancer	0.000836	0.00376	CcSEcCtD
Metyrapone—Pancytopenia—Capecitabine—kidney cancer	0.000828	0.00372	CcSEcCtD
Metyrapone—Abdominal pain—Erlotinib—kidney cancer	0.000822	0.00369	CcSEcCtD
Metyrapone—Nausea—Pazopanib—kidney cancer	0.00081	0.00364	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000807	0.00363	CcSEcCtD
Metyrapone—Hypertension—Vincristine—kidney cancer	0.000805	0.00362	CcSEcCtD
Metyrapone—Pain—Sorafenib—kidney cancer	0.0008	0.00359	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Sunitinib—kidney cancer	0.000777	0.00349	CcSEcCtD
Metyrapone—Angiopathy—Paclitaxel—kidney cancer	0.000772	0.00347	CcSEcCtD
Metyrapone—Pain—Sunitinib—kidney cancer	0.000769	0.00346	CcSEcCtD
Metyrapone—Gastrointestinal pain—Sorafenib—kidney cancer	0.000765	0.00343	CcSEcCtD
Metyrapone—Hypertension—Gemcitabine—kidney cancer	0.000764	0.00343	CcSEcCtD
Metyrapone—Alopecia—Paclitaxel—kidney cancer	0.000752	0.00338	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.000748	0.00336	CcSEcCtD
Metyrapone—Nervous system disorder—Vincristine—kidney cancer	0.000746	0.00335	CcSEcCtD
Metyrapone—Abdominal pain—Sorafenib—kidney cancer	0.000739	0.00332	CcSEcCtD
Metyrapone—Gastrointestinal pain—Sunitinib—kidney cancer	0.000736	0.0033	CcSEcCtD
Metyrapone—Pain—Dactinomycin—kidney cancer	0.000728	0.00327	CcSEcCtD
Metyrapone—Dizziness—Vinblastine—kidney cancer	0.000715	0.00321	CcSEcCtD
Metyrapone—Dizziness—Everolimus—kidney cancer	0.000712	0.0032	CcSEcCtD
Metyrapone—Abdominal pain—Sunitinib—kidney cancer	0.000711	0.00319	CcSEcCtD
Metyrapone—Hypotension—Vincristine—kidney cancer	0.000711	0.00319	CcSEcCtD
Metyrapone—Nervous system disorder—Gemcitabine—kidney cancer	0.000708	0.00318	CcSEcCtD
Metyrapone—Skin disorder—Gemcitabine—kidney cancer	0.000701	0.00315	CcSEcCtD
Metyrapone—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000697	0.00313	CcSEcCtD
Metyrapone—Vomiting—Vinblastine—kidney cancer	0.000688	0.00309	CcSEcCtD
Metyrapone—Dizziness—Erlotinib—kidney cancer	0.000687	0.00309	CcSEcCtD
Metyrapone—Vomiting—Everolimus—kidney cancer	0.000685	0.00308	CcSEcCtD
Metyrapone—Headache—Vinblastine—kidney cancer	0.000678	0.00304	CcSEcCtD
Metyrapone—Headache—Everolimus—kidney cancer	0.000675	0.00303	CcSEcCtD
Metyrapone—Hypotension—Gemcitabine—kidney cancer	0.000675	0.00303	CcSEcCtD
Metyrapone—Abdominal pain—Dactinomycin—kidney cancer	0.000673	0.00302	CcSEcCtD
Metyrapone—Vomiting—Erlotinib—kidney cancer	0.000661	0.00297	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Vincristine—kidney cancer	0.000657	0.00295	CcSEcCtD
Metyrapone—Headache—Erlotinib—kidney cancer	0.000651	0.00292	CcSEcCtD
Metyrapone—Pain—Vincristine—kidney cancer	0.000651	0.00292	CcSEcCtD
Metyrapone—Nausea—Vinblastine—kidney cancer	0.000642	0.00289	CcSEcCtD
Metyrapone—Nausea—Everolimus—kidney cancer	0.00064	0.00287	CcSEcCtD
Metyrapone—Hypertension—Paclitaxel—kidney cancer	0.000639	0.00287	CcSEcCtD
Metyrapone—Angiopathy—Capecitabine—kidney cancer	0.000634	0.00285	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000626	0.00281	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000623	0.0028	CcSEcCtD
Metyrapone—Gastrointestinal pain—Vincristine—kidney cancer	0.000622	0.0028	CcSEcCtD
Metyrapone—Dizziness—Sorafenib—kidney cancer	0.000618	0.00278	CcSEcCtD
Metyrapone—Pain—Gemcitabine—kidney cancer	0.000617	0.00277	CcSEcCtD
Metyrapone—Nausea—Erlotinib—kidney cancer	0.000617	0.00277	CcSEcCtD
Metyrapone—Alopecia—Capecitabine—kidney cancer	0.000617	0.00277	CcSEcCtD
Metyrapone—Abdominal pain—Vincristine—kidney cancer	0.000602	0.0027	CcSEcCtD
Metyrapone—Dizziness—Sunitinib—kidney cancer	0.000595	0.00267	CcSEcCtD
Metyrapone—Vomiting—Sorafenib—kidney cancer	0.000595	0.00267	CcSEcCtD
Metyrapone—Nervous system disorder—Paclitaxel—kidney cancer	0.000593	0.00266	CcSEcCtD
Metyrapone—Skin disorder—Paclitaxel—kidney cancer	0.000587	0.00264	CcSEcCtD
Metyrapone—Headache—Sorafenib—kidney cancer	0.000586	0.00263	CcSEcCtD
Metyrapone—Vomiting—Sunitinib—kidney cancer	0.000572	0.00257	CcSEcCtD
Metyrapone—Hypotension—Paclitaxel—kidney cancer	0.000565	0.00254	CcSEcCtD
Metyrapone—Headache—Sunitinib—kidney cancer	0.000564	0.00253	CcSEcCtD
Metyrapone—Nausea—Sorafenib—kidney cancer	0.000555	0.00249	CcSEcCtD
Metyrapone—Vomiting—Dactinomycin—kidney cancer	0.000542	0.00243	CcSEcCtD
Metyrapone—Nausea—Sunitinib—kidney cancer	0.000534	0.0024	CcSEcCtD
Metyrapone—Pancytopenia—Doxorubicin—kidney cancer	0.000534	0.0024	CcSEcCtD
Metyrapone—Hypertension—Capecitabine—kidney cancer	0.000525	0.00236	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000522	0.00234	CcSEcCtD
Metyrapone—Pain—Paclitaxel—kidney cancer	0.000517	0.00232	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000514	0.00231	CcSEcCtD
Metyrapone—Nausea—Dactinomycin—kidney cancer	0.000506	0.00227	CcSEcCtD
Metyrapone—Dizziness—Vincristine—kidney cancer	0.000503	0.00226	CcSEcCtD
Metyrapone—Gastrointestinal pain—Paclitaxel—kidney cancer	0.000494	0.00222	CcSEcCtD
Metyrapone—Nervous system disorder—Capecitabine—kidney cancer	0.000487	0.00219	CcSEcCtD
Metyrapone—Vomiting—Vincristine—kidney cancer	0.000484	0.00217	CcSEcCtD
Metyrapone—Skin disorder—Capecitabine—kidney cancer	0.000482	0.00216	CcSEcCtD
Metyrapone—Abdominal pain—Paclitaxel—kidney cancer	0.000478	0.00215	CcSEcCtD
Metyrapone—Headache—Vincristine—kidney cancer	0.000477	0.00214	CcSEcCtD
Metyrapone—Hypotension—Capecitabine—kidney cancer	0.000464	0.00208	CcSEcCtD
Metyrapone—Vomiting—Gemcitabine—kidney cancer	0.000459	0.00206	CcSEcCtD
Metyrapone—Headache—Gemcitabine—kidney cancer	0.000452	0.00203	CcSEcCtD
Metyrapone—Nausea—Vincristine—kidney cancer	0.000452	0.00203	CcSEcCtD
Metyrapone—Nausea—Gemcitabine—kidney cancer	0.000429	0.00193	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000428	0.00192	CcSEcCtD
Metyrapone—Pain—Capecitabine—kidney cancer	0.000424	0.00191	CcSEcCtD
Metyrapone—Angiopathy—Doxorubicin—kidney cancer	0.000408	0.00183	CcSEcCtD
Metyrapone—Gastrointestinal pain—Capecitabine—kidney cancer	0.000406	0.00182	CcSEcCtD
Metyrapone—Dizziness—Paclitaxel—kidney cancer	0.0004	0.0018	CcSEcCtD
Metyrapone—Alopecia—Doxorubicin—kidney cancer	0.000398	0.00179	CcSEcCtD
Metyrapone—Abdominal pain—Capecitabine—kidney cancer	0.000392	0.00176	CcSEcCtD
Metyrapone—Vomiting—Paclitaxel—kidney cancer	0.000384	0.00173	CcSEcCtD
Metyrapone—Headache—Paclitaxel—kidney cancer	0.000379	0.0017	CcSEcCtD
Metyrapone—Nausea—Paclitaxel—kidney cancer	0.000359	0.00161	CcSEcCtD
Metyrapone—Hypertension—Doxorubicin—kidney cancer	0.000338	0.00152	CcSEcCtD
Metyrapone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000331	0.00149	CcSEcCtD
Metyrapone—Dizziness—Capecitabine—kidney cancer	0.000328	0.00147	CcSEcCtD
Metyrapone—Vomiting—Capecitabine—kidney cancer	0.000315	0.00142	CcSEcCtD
Metyrapone—Nervous system disorder—Doxorubicin—kidney cancer	0.000314	0.00141	CcSEcCtD
Metyrapone—Headache—Capecitabine—kidney cancer	0.000311	0.0014	CcSEcCtD
Metyrapone—Skin disorder—Doxorubicin—kidney cancer	0.000311	0.0014	CcSEcCtD
Metyrapone—Hypotension—Doxorubicin—kidney cancer	0.000299	0.00134	CcSEcCtD
Metyrapone—Nausea—Capecitabine—kidney cancer	0.000295	0.00132	CcSEcCtD
Metyrapone—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000276	0.00124	CcSEcCtD
Metyrapone—Pain—Doxorubicin—kidney cancer	0.000273	0.00123	CcSEcCtD
Metyrapone—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000261	0.00117	CcSEcCtD
Metyrapone—Abdominal pain—Doxorubicin—kidney cancer	0.000253	0.00114	CcSEcCtD
Metyrapone—Dizziness—Doxorubicin—kidney cancer	0.000211	0.00095	CcSEcCtD
Metyrapone—Vomiting—Doxorubicin—kidney cancer	0.000203	0.000913	CcSEcCtD
Metyrapone—Headache—Doxorubicin—kidney cancer	0.0002	0.0009	CcSEcCtD
Metyrapone—Nausea—Doxorubicin—kidney cancer	0.00019	0.000853	CcSEcCtD
Metyrapone—CYP2A6—Fluoropyrimidine Activity—TP53—kidney cancer	0.000179	0.00155	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000178	0.00154	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—GSTT1—kidney cancer	0.000176	0.00153	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—GSTP1—kidney cancer	0.000176	0.00153	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ALAD—kidney cancer	0.000175	0.00151	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ST3GAL2—kidney cancer	0.000171	0.00148	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—FH—kidney cancer	0.000169	0.00146	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—APRT—kidney cancer	0.000169	0.00146	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ALDH1A1—kidney cancer	0.000167	0.00145	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000165	0.00143	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—PTGS1—kidney cancer	0.000165	0.00143	CbGpPWpGaD
Metyrapone—CYP2A6—NRF2 pathway—GSTM1—kidney cancer	0.000162	0.0014	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000161	0.0014	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PDHB—kidney cancer	0.000161	0.00139	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—SLC5A3—kidney cancer	0.00016	0.00139	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PGK1—kidney cancer	0.00016	0.00139	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GPC3—kidney cancer	0.000159	0.00138	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—LDHB—kidney cancer	0.000157	0.00136	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CA2—kidney cancer	0.000155	0.00134	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—GSTP1—kidney cancer	0.000155	0.00134	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CCBL1—kidney cancer	0.000151	0.00131	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ALAD—kidney cancer	0.000151	0.00131	CbGpPWpGaD
Metyrapone—CYP2E1—Phase 1 - Functionalization of compounds—POMC—kidney cancer	0.000149	0.00129	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ST3GAL2—kidney cancer	0.000147	0.00127	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	0.000144	0.00125	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ALDH1A1—kidney cancer	0.000144	0.00125	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—GSTM1—kidney cancer	0.000142	0.00123	CbGpPWpGaD
Metyrapone—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	0.000142	0.00123	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	0.000139	0.0012	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—SLC5A3—kidney cancer	0.000138	0.00119	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PGK1—kidney cancer	0.000138	0.00119	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.000137	0.00118	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CA9—kidney cancer	0.000136	0.00118	CbGpPWpGaD
Metyrapone—CYP2E1—Vitamin A and Carotenoid Metabolism—MAPK1—kidney cancer	0.000136	0.00118	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—LDHB—kidney cancer	0.000135	0.00117	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—CYP1A1—kidney cancer	0.000135	0.00117	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000133	0.00115	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PPAT—kidney cancer	0.000131	0.00113	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GLIPR1—kidney cancer	0.000131	0.00113	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	0.000129	0.00112	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	0.000128	0.00111	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—GSTP1—kidney cancer	0.000122	0.00106	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—FH—kidney cancer	0.000122	0.00105	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—APRT—kidney cancer	0.000122	0.00105	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—GSTP1—kidney cancer	0.000121	0.00104	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	0.000119	0.00103	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ACY1—kidney cancer	0.000119	0.00103	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CA9—kidney cancer	0.000117	0.00102	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CRABP1—kidney cancer	0.000116	0.001	CbGpPWpGaD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000115	0.000992	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	0.000115	0.000992	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GPC3—kidney cancer	0.000115	0.000992	CbGpPWpGaD
Metyrapone—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000113	0.000979	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—GSTM1—kidney cancer	0.000112	0.000972	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000112	0.000968	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CA2—kidney cancer	0.000112	0.000965	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—GSTM1—kidney cancer	0.000111	0.000958	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ALAD—kidney cancer	0.000109	0.00094	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000108	0.000935	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ITPR2—kidney cancer	0.000108	0.000931	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—CYP1A1—kidney cancer	0.000106	0.000921	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ST3GAL2—kidney cancer	0.000106	0.000918	CbGpPWpGaD
Metyrapone—CYP2E1—Metapathway biotransformation—CYP1A1—kidney cancer	0.000105	0.000908	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ALDH1A1—kidney cancer	0.000104	0.000897	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PDHB—kidney cancer	0.000101	0.000872	CbGpPWpGaD
Metyrapone—CYP2A6—Biological oxidations—POMC—kidney cancer	0.0001	0.000869	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CRABP1—kidney cancer	9.98e-05	0.000863	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PGK1—kidney cancer	9.94e-05	0.00086	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SLC5A3—kidney cancer	9.94e-05	0.00086	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	9.92e-05	0.000859	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTT1—kidney cancer	9.82e-05	0.000849	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ACHE—kidney cancer	9.82e-05	0.000849	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—LDHB—kidney cancer	9.75e-05	0.000843	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CCBL1—kidney cancer	9.47e-05	0.00082	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ACY1—kidney cancer	9.37e-05	0.00081	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	9.3e-05	0.000805	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—SCARB1—kidney cancer	9.29e-05	0.000804	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ITPR2—kidney cancer	9.28e-05	0.000803	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS1—kidney cancer	9.2e-05	0.000796	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PSMD7—kidney cancer	9.02e-05	0.00078	CbGpPWpGaD
Metyrapone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	8.55e-05	0.00074	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—POMC—kidney cancer	8.55e-05	0.00074	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—BCHE—kidney cancer	8.55e-05	0.00074	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.53e-05	0.000738	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTT1—kidney cancer	8.46e-05	0.000732	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ACHE—kidney cancer	8.46e-05	0.000732	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CA9—kidney cancer	8.45e-05	0.000731	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—SLC5A5—kidney cancer	8.45e-05	0.000731	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	8.26e-05	0.000715	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PPAT—kidney cancer	8.22e-05	0.000711	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GLIPR1—kidney cancer	8.22e-05	0.000711	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTT1—kidney cancer	8.18e-05	0.000708	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—SLC2A1—kidney cancer	8.16e-05	0.000706	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—SCARB1—kidney cancer	8.01e-05	0.000693	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PDHB—kidney cancer	7.96e-05	0.000689	CbGpPWpGaD
Metyrapone—CYP2E1—Biological oxidations—POMC—kidney cancer	7.94e-05	0.000687	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS1—kidney cancer	7.93e-05	0.000686	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	7.92e-05	0.000685	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PSMD7—kidney cancer	7.77e-05	0.000673	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—PTGS1—kidney cancer	7.67e-05	0.000663	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—FH—kidney cancer	7.64e-05	0.000661	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—APRT—kidney cancer	7.64e-05	0.000661	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CCBL1—kidney cancer	7.49e-05	0.000648	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—BCHE—kidney cancer	7.37e-05	0.000638	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—SLC5A5—kidney cancer	7.28e-05	0.00063	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CRABP1—kidney cancer	7.19e-05	0.000622	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GPC3—kidney cancer	7.18e-05	0.000621	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—SLC2A1—kidney cancer	7.03e-05	0.000608	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CA2—kidney cancer	6.99e-05	0.000604	CbGpPWpGaD
Metyrapone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.93e-05	0.0006	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	6.9e-05	0.000597	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	6.82e-05	0.00059	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ALAD—kidney cancer	6.81e-05	0.000589	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTP1—kidney cancer	6.8e-05	0.000589	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ITPR2—kidney cancer	6.68e-05	0.000578	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ST3GAL2—kidney cancer	6.64e-05	0.000575	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ALDH1A1—kidney cancer	6.49e-05	0.000562	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GLIPR1—kidney cancer	6.49e-05	0.000562	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PPAT—kidney cancer	6.49e-05	0.000562	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—ABCB1—kidney cancer	6.44e-05	0.000557	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—GSTM1—kidney cancer	6.25e-05	0.000541	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PGK1—kidney cancer	6.23e-05	0.000539	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC5A3—kidney cancer	6.23e-05	0.000539	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—POMC—kidney cancer	6.16e-05	0.000533	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—LDHB—kidney cancer	6.11e-05	0.000528	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTT1—kidney cancer	6.09e-05	0.000527	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ACHE—kidney cancer	6.09e-05	0.000527	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—APRT—kidney cancer	6.04e-05	0.000522	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—FH—kidney cancer	6.04e-05	0.000522	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	5.95e-05	0.000515	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—CYP1A1—kidney cancer	5.93e-05	0.000513	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTP1—kidney cancer	5.86e-05	0.000507	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SCARB1—kidney cancer	5.77e-05	0.000499	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS1—kidney cancer	5.71e-05	0.000494	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GPC3—kidney cancer	5.67e-05	0.000491	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTP1—kidney cancer	5.67e-05	0.000491	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PSMD7—kidney cancer	5.6e-05	0.000484	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	5.59e-05	0.000484	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—ABCB1—kidney cancer	5.55e-05	0.00048	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CA2—kidney cancer	5.52e-05	0.000478	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—GSTM1—kidney cancer	5.39e-05	0.000466	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ALAD—kidney cancer	5.38e-05	0.000465	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—BCHE—kidney cancer	5.31e-05	0.000459	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CA9—kidney cancer	5.29e-05	0.000458	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ST3GAL2—kidney cancer	5.25e-05	0.000454	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SLC5A5—kidney cancer	5.24e-05	0.000453	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—GSTM1—kidney cancer	5.21e-05	0.000451	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	5.14e-05	0.000445	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ALDH1A1—kidney cancer	5.13e-05	0.000444	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—CYP1A1—kidney cancer	5.11e-05	0.000442	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—SLC2A1—kidney cancer	5.06e-05	0.000438	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	4.94e-05	0.000427	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PGK1—kidney cancer	4.92e-05	0.000426	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC5A3—kidney cancer	4.92e-05	0.000426	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	4.91e-05	0.000425	CbGpPWpGaD
Metyrapone—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	4.87e-05	0.000421	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.87e-05	0.000421	CbGpPWpGaD
Metyrapone—ABCC3—Transmembrane transport of small molecules—RAF1—kidney cancer	4.83e-05	0.000418	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—LDHB—kidney cancer	4.82e-05	0.000417	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CRABP1—kidney cancer	4.5e-05	0.000389	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—POMC—kidney cancer	4.42e-05	0.000382	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ACY1—kidney cancer	4.35e-05	0.000376	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	4.28e-05	0.000371	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTP1—kidney cancer	4.22e-05	0.000365	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.2e-05	0.000363	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ITPR2—kidney cancer	4.18e-05	0.000362	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CA9—kidney cancer	4.18e-05	0.000362	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—ABCB1—kidney cancer	4e-05	0.000346	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—GSTM1—kidney cancer	3.88e-05	0.000336	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTT1—kidney cancer	3.82e-05	0.00033	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ACHE—kidney cancer	3.82e-05	0.00033	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—POMC—kidney cancer	3.81e-05	0.000329	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PDHB—kidney cancer	3.69e-05	0.00032	CbGpPWpGaD
Metyrapone—CYP3A4—Biological oxidations—POMC—kidney cancer	3.68e-05	0.000319	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—CYP1A1—kidney cancer	3.68e-05	0.000318	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SCARB1—kidney cancer	3.61e-05	0.000312	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS1—kidney cancer	3.58e-05	0.000309	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CRABP1—kidney cancer	3.56e-05	0.000308	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTGS2—kidney cancer	3.53e-05	0.000305	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PSMD7—kidney cancer	3.51e-05	0.000303	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CCBL1—kidney cancer	3.47e-05	0.000301	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—BCHE—kidney cancer	3.32e-05	0.000288	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ITPR2—kidney cancer	3.31e-05	0.000286	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC5A5—kidney cancer	3.28e-05	0.000284	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—SLC2A1—kidney cancer	3.17e-05	0.000274	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PTEN—kidney cancer	3.07e-05	0.000266	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTGS2—kidney cancer	3.04e-05	0.000263	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	3.02e-05	0.000261	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ACHE—kidney cancer	3.02e-05	0.000261	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTT1—kidney cancer	3.02e-05	0.000261	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PPAT—kidney cancer	3.01e-05	0.000261	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GLIPR1—kidney cancer	3.01e-05	0.000261	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SCARB1—kidney cancer	2.85e-05	0.000247	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS1—kidney cancer	2.83e-05	0.000244	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—APRT—kidney cancer	2.8e-05	0.000242	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—FH—kidney cancer	2.8e-05	0.000242	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PSMD7—kidney cancer	2.77e-05	0.00024	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—POMC—kidney cancer	2.74e-05	0.000237	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PTEN—kidney cancer	2.65e-05	0.000229	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTP1—kidney cancer	2.65e-05	0.000229	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GPC3—kidney cancer	2.63e-05	0.000228	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—BCHE—kidney cancer	2.63e-05	0.000227	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC5A5—kidney cancer	2.59e-05	0.000224	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CA2—kidney cancer	2.56e-05	0.000222	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—SLC2A1—kidney cancer	2.51e-05	0.000217	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—ABCB1—kidney cancer	2.5e-05	0.000217	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALAD—kidney cancer	2.5e-05	0.000216	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ST3GAL2—kidney cancer	2.44e-05	0.000211	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—GSTM1—kidney cancer	2.43e-05	0.00021	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ALDH1A1—kidney cancer	2.38e-05	0.000206	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—CYP1A1—kidney cancer	2.3e-05	0.000199	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PGK1—kidney cancer	2.28e-05	0.000197	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC5A3—kidney cancer	2.28e-05	0.000197	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—LDHB—kidney cancer	2.24e-05	0.000194	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTGS2—kidney cancer	2.19e-05	0.000189	CbGpPWpGaD
Metyrapone—CYP11B2—Metabolism—PIK3CA—kidney cancer	2.17e-05	0.000188	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTP1—kidney cancer	2.09e-05	0.000181	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—ABCB1—kidney cancer	1.98e-05	0.000171	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CA9—kidney cancer	1.94e-05	0.000168	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—GSTM1—kidney cancer	1.92e-05	0.000166	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PTEN—kidney cancer	1.91e-05	0.000165	CbGpPWpGaD
Metyrapone—CYP11B1—Metabolism—PIK3CA—kidney cancer	1.87e-05	0.000162	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—CYP1A1—kidney cancer	1.82e-05	0.000158	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—POMC—kidney cancer	1.72e-05	0.000149	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CRABP1—kidney cancer	1.65e-05	0.000143	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ITPR2—kidney cancer	1.53e-05	0.000133	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTT1—kidney cancer	1.4e-05	0.000121	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ACHE—kidney cancer	1.4e-05	0.000121	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTGS2—kidney cancer	1.37e-05	0.000119	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—POMC—kidney cancer	1.36e-05	0.000117	CbGpPWpGaD
Metyrapone—ABCC3—Metabolism—PIK3CA—kidney cancer	1.35e-05	0.000116	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SCARB1—kidney cancer	1.32e-05	0.000115	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS1—kidney cancer	1.31e-05	0.000113	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PSMD7—kidney cancer	1.29e-05	0.000111	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—BCHE—kidney cancer	1.22e-05	0.000105	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC5A5—kidney cancer	1.2e-05	0.000104	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PTEN—kidney cancer	1.2e-05	0.000103	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—SLC2A1—kidney cancer	1.16e-05	0.000101	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTGS2—kidney cancer	1.08e-05	9.37e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTP1—kidney cancer	9.7e-06	8.39e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PTEN—kidney cancer	9.44e-06	8.17e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—ABCB1—kidney cancer	9.18e-06	7.94e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—GSTM1—kidney cancer	8.91e-06	7.71e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—CYP1A1—kidney cancer	8.45e-06	7.31e-05	CbGpPWpGaD
Metyrapone—CYP2A6—Metabolism—PIK3CA—kidney cancer	8.43e-06	7.29e-05	CbGpPWpGaD
Metyrapone—CYP2E1—Metabolism—PIK3CA—kidney cancer	6.66e-06	5.76e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—POMC—kidney cancer	6.3e-06	5.45e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTGS2—kidney cancer	5.02e-06	4.35e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PTEN—kidney cancer	4.38e-06	3.79e-05	CbGpPWpGaD
Metyrapone—CYP3A4—Metabolism—PIK3CA—kidney cancer	3.09e-06	2.67e-05	CbGpPWpGaD
